Tags

Type your tag names separated by a space and hit enter

Time To Revise COPD Treatment Algorithm.
Int J Chron Obstruct Pulmon Dis 2019; 14:2229-2234IJ

Abstract

In 2017, a new two-step algorithm for the treatment of COPD was proposed. This algorithm was based on the severity of symptoms and phenotypes or treatable traits, and patient-specialised assessment targeting eosinophilic inflammation, chronic bronchitis, and frequent infections is recommended after exacerbation occurs despite maximal bronchodilation therapy. However, recent studies have revealed the clinical characteristics of patients who should have second controllers added, such as ICS. We again realized that treatable traits should be assessed and intervened for as early as possible. Moreover, the treatment algorithm is necessary to be adapted to the situation of clinical practice, taking into account the characteristics of the patients. The time to revise COPD treatment algorithm has come and we propose a new 3-step parallel approach for initial COPD treatment. After the diagnosis of COPD, the first assessment is to divide into two categories based on the usual clinical characteristics for patients with COPD and the specific clinical characteristics for each patient with concomitant disease. In the former, the assessment should be based on the level of dyspnea and the frequency of exacerbations. After the assessment, mono- or dual bronchodilator should be selected. In the latter, the assessment should be based on asthma characteristics, chronic bronchitis, and chronic heart failure. After the assessment, patients with asthmatic characteristics may consider treatment with ICS, while patients with chronic bronchitis may consider treatment with roflumilast and/or macrolide, while patients with chronic heart failure may consider treatment with selective β1-blocker. The 3-step parallel approach is completed by adding an additional therapy for patients with concomitant disease to essential therapy for patients with COPD. In addition, it is important to review the response around 4 weeks after the initial therapy. This COPD management proposal might be considered as an approach based on patients' clinical characteristics and on personalized therapy.

Authors+Show Affiliations

Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.Department of Medicine and Clinical Science, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.Department of Pneumology, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Barcelona, Spain.Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, The University of Texas Health Science Center, San Antonio, TX, USA. Pulmonary Diseases Section, Audie L. Murphy Memorial VA Hospital, South Texas Veterans Health Care System, San Antonio, TX, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31631994

Citation

Matsunaga, Kazuto, et al. "Time to Revise COPD Treatment Algorithm." International Journal of Chronic Obstructive Pulmonary Disease, vol. 14, 2019, pp. 2229-2234.
Matsunaga K, Oishi K, Miravitlles M, et al. Time To Revise COPD Treatment Algorithm. Int J Chron Obstruct Pulmon Dis. 2019;14:2229-2234.
Matsunaga, K., Oishi, K., Miravitlles, M., & Anzueto, A. (2019). Time To Revise COPD Treatment Algorithm. International Journal of Chronic Obstructive Pulmonary Disease, 14, pp. 2229-2234. doi:10.2147/COPD.S219051.
Matsunaga K, et al. Time to Revise COPD Treatment Algorithm. Int J Chron Obstruct Pulmon Dis. 2019;14:2229-2234. PubMed PMID: 31631994.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Time To Revise COPD Treatment Algorithm. AU - Matsunaga,Kazuto, AU - Oishi,Keiji, AU - Miravitlles,Marc, AU - Anzueto,Antonio, Y1 - 2019/09/27/ PY - 2019/06/11/received PY - 2019/09/16/accepted PY - 2019/10/22/entrez PY - 2019/10/22/pubmed PY - 2019/10/22/medline KW - ICS KW - parallel approach KW - personalized therapy KW - treatable traits SP - 2229 EP - 2234 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 14 N2 - In 2017, a new two-step algorithm for the treatment of COPD was proposed. This algorithm was based on the severity of symptoms and phenotypes or treatable traits, and patient-specialised assessment targeting eosinophilic inflammation, chronic bronchitis, and frequent infections is recommended after exacerbation occurs despite maximal bronchodilation therapy. However, recent studies have revealed the clinical characteristics of patients who should have second controllers added, such as ICS. We again realized that treatable traits should be assessed and intervened for as early as possible. Moreover, the treatment algorithm is necessary to be adapted to the situation of clinical practice, taking into account the characteristics of the patients. The time to revise COPD treatment algorithm has come and we propose a new 3-step parallel approach for initial COPD treatment. After the diagnosis of COPD, the first assessment is to divide into two categories based on the usual clinical characteristics for patients with COPD and the specific clinical characteristics for each patient with concomitant disease. In the former, the assessment should be based on the level of dyspnea and the frequency of exacerbations. After the assessment, mono- or dual bronchodilator should be selected. In the latter, the assessment should be based on asthma characteristics, chronic bronchitis, and chronic heart failure. After the assessment, patients with asthmatic characteristics may consider treatment with ICS, while patients with chronic bronchitis may consider treatment with roflumilast and/or macrolide, while patients with chronic heart failure may consider treatment with selective β1-blocker. The 3-step parallel approach is completed by adding an additional therapy for patients with concomitant disease to essential therapy for patients with COPD. In addition, it is important to review the response around 4 weeks after the initial therapy. This COPD management proposal might be considered as an approach based on patients' clinical characteristics and on personalized therapy. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/31631994/Time_To_Revise_COPD_Treatment_Algorithm L2 - https://dx.doi.org/10.2147/COPD.S219051 DB - PRIME DP - Unbound Medicine ER -